[go: up one dir, main page]

AR067928A1 - Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos - Google Patents

Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos

Info

Publication number
AR067928A1
AR067928A1 ARP080103532A ARP080103532A AR067928A1 AR 067928 A1 AR067928 A1 AR 067928A1 AR P080103532 A ARP080103532 A AR P080103532A AR P080103532 A ARP080103532 A AR P080103532A AR 067928 A1 AR067928 A1 AR 067928A1
Authority
AR
Argentina
Prior art keywords
unions
profiles
reasons
context
rna sequences
Prior art date
Application number
ARP080103532A
Other languages
English (en)
Inventor
Marion Jurk
Vollmer Jorg Heinz
Original Assignee
Coley Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067928(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coley Pharm Gmbh filed Critical Coley Pharm Gmbh
Publication of AR067928A1 publication Critical patent/AR067928A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)

Abstract

Polímeros inmunoestimulantes que contienen algunos motivos ARN inmunoestimulantes dependientes de la secuencia y métodos para el uso de tales polímeros inmunoestimulantes y composiciones que contienen tales polímeros se proveen de acuerdo con la solicitud. Los motivos ARN inmunoestimulantes dependientes de las secuencias y los polímeros que incorporan tales motivos son inductores potentes y selectivos de TLR 7 y la citoquina IFN-7 asociada a TLR7.
ARP080103532A 2007-08-13 2008-08-13 Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos AR067928A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96444807P 2007-08-13 2007-08-13

Publications (1)

Publication Number Publication Date
AR067928A1 true AR067928A1 (es) 2009-10-28

Family

ID=40351228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103532A AR067928A1 (es) 2007-08-13 2008-08-13 Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos

Country Status (22)

Country Link
US (3) US8128944B2 (es)
EP (1) EP2179039B1 (es)
JP (1) JP4847609B2 (es)
KR (1) KR20100045508A (es)
CN (1) CN101821392B (es)
AR (1) AR067928A1 (es)
AU (1) AU2008288241B2 (es)
BR (1) BRPI0814260B8 (es)
CA (1) CA2696630C (es)
CL (1) CL2008002371A1 (es)
CO (1) CO6260153A2 (es)
DK (1) DK2179039T3 (es)
ES (1) ES2703876T3 (es)
MX (1) MX2010001014A (es)
NZ (1) NZ582972A (es)
PL (1) PL2179039T3 (es)
PT (1) PT2179039T (es)
RU (1) RU2435851C2 (es)
SI (1) SI2179039T1 (es)
TR (1) TR201820474T4 (es)
TW (1) TW200916106A (es)
WO (1) WO2009022216A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001014A (es) * 2007-08-13 2010-03-01 Coley Pharm Gmbh Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos.
US9370531B2 (en) * 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US9844592B2 (en) * 2011-07-18 2017-12-19 Icahn School Of Medicine At Mount Sinai Bacterial RNAs as vaccine adjuvants
WO2015187966A1 (en) * 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US11932857B2 (en) * 2017-12-15 2024-03-19 Elanco Animal Health Gmbh Immunostimulatory oligonucleotides
WO2024030844A1 (en) * 2022-08-01 2024-02-08 University Of Mississippi Choline carboxylic acid based ionic liquids as antimicrobial agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
ZA951877B (en) * 1994-03-07 1996-09-09 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates
WO2000047601A1 (en) * 1999-02-15 2000-08-17 Nippon Shinyaku Co. Ltd. Shortened-chain polynucleotides and process for the preparation thereof
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
RU2185818C1 (ru) * 2001-07-10 2002-07-27 НИИ "Молекулярной медицины" Московской медицинской академии им. И.М. Сеченова Композиция для лечения легочных инфекций
SG177000A1 (en) * 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
NZ573064A (en) * 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
WO2003086820A1 (fr) 2002-04-12 2003-10-23 Aisin Aw Co., Ltd. Systeme de gestion d'alimentation pour dispositif installe sur un vehicule
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
AU2003300919A1 (en) * 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
EP1648913A4 (en) * 2003-07-15 2008-09-10 Idera Pharmaceuticals Inc SYNERGISTIC STIMULATION OF THE IMMUNE SYSTEM WITH IMMUNOSTIMULATING OLIGONUCLEOTIDES AND / OR IMMUNOMER COMPOUNDS RELATED TO CYTOKINES AND / OR CHEMOTHERAPEAN MEDICAMENTS OR RADIATION THERAPY
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
CA2555390C (en) * 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8076068B2 (en) 2005-09-14 2011-12-13 Gunther Hartmann Method for determining immunostimulatory activity of RNA oligonucleotides
AU2006318464B2 (en) * 2005-11-25 2011-02-17 Zoetis Belgium Sa Immunostimulatory oligoribonucleotides
MX2010001014A (es) * 2007-08-13 2010-03-01 Coley Pharm Gmbh Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos.

Also Published As

Publication number Publication date
RU2010104618A (ru) 2011-09-20
PL2179039T3 (pl) 2019-03-29
NZ582972A (en) 2011-09-30
SI2179039T1 (sl) 2019-01-31
RU2435851C2 (ru) 2011-12-10
US8128944B2 (en) 2012-03-06
AU2008288241A1 (en) 2009-02-19
HK1143741A1 (en) 2011-01-14
US20100272785A1 (en) 2010-10-28
WO2009022216A2 (en) 2009-02-19
DK2179039T3 (en) 2019-01-07
US8227447B2 (en) 2012-07-24
US20120121648A1 (en) 2012-05-17
CN101821392A (zh) 2010-09-01
ES2703876T3 (es) 2019-03-12
TW200916106A (en) 2009-04-16
CA2696630C (en) 2014-04-01
EP2179039A2 (en) 2010-04-28
BRPI0814260B8 (pt) 2021-05-25
JP2010536739A (ja) 2010-12-02
WO2009022216A9 (en) 2009-04-30
US8466124B2 (en) 2013-06-18
TR201820474T4 (tr) 2019-01-21
BRPI0814260A2 (pt) 2015-03-31
CO6260153A2 (es) 2011-03-22
CN101821392B (zh) 2013-04-17
WO2009022216A3 (en) 2009-06-04
US20120258140A1 (en) 2012-10-11
EP2179039B1 (en) 2018-10-31
MX2010001014A (es) 2010-03-01
CL2008002371A1 (es) 2009-07-03
BRPI0814260B1 (pt) 2019-11-12
JP4847609B2 (ja) 2011-12-28
AU2008288241B2 (en) 2011-12-01
PT2179039T (pt) 2019-01-11
CA2696630A1 (en) 2009-02-19
KR20100045508A (ko) 2010-05-03

Similar Documents

Publication Publication Date Title
AR067928A1 (es) Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos
CY1120032T1 (el) Πυραζολυλικες και πυριμιδιυλικες τρικυκλικες ενονες ως αντιοξειδωτικοι ρυθμιστες φλεγμονης
ES2689523T3 (es) Composiciones a base de ARNM del gen CFTR y métodos y usos relacionados
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
BR112014000236A2 (pt) lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
PA8676201A1 (es) Metodos para sintetizar 3-cianoquinolinas sustituidad y sus intermediarios
MX384824B (es) Compuestos conjugados antisentido y su uso.
ES2534304T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
IN2010KN00195A (es)
AR072034A1 (es) Arn circular monocatenario y metodo para producirlo
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
CR20140544A (es) Compuestos para inhibir la progresión mitotica
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
MX353827B (es) Formas de rifaximina y usos de la misma.
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
BR112015020517A2 (pt) produto abrasivo, superfície de produto abrasivo, aparelho, uso de um produto abrasivo, e, método para obter um produto abrasivo
CL2017002460A1 (es) Composición de ácidos grasos y derivados n-acilo de sarcosina para flotación mejorada de minerales no sulfuros
AR067361A1 (es) 4- cloro-4- alcoxi-1,1,1- trifluoro -2- butanonas, su preparacion y su uso para preparar 4- alcoxi-1,1,1- trifluoro-3 -buten-2- onas
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
CO6551754A2 (es) 7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso
GT200500385A (es) Aminoalcoholes triciclicos, procedimientos para su preparacion y su uso como inhibidores de inflamacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal